Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.10%
#4 BOOK OF MEME BOOK OF MEME +14.69%
#5 MarsCoin MarsCoin +12.77%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.37%
#7 Nockchain Nockchain +11.14%
#8 SkyAI SkyAI +9.10%
#9 Lighter Lighter +8.81%
#10 Monad Monad +8.69%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Neurizon Therapeutics Limited Neurizon Therapeutics Limited

Neurizon Therapeutics Limited

NUZ
Rank in Stocks #27538
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops... Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Share Price
$0.0416118
Market Cap
$32.25M
Change (1 day)
-1.67%
Change (1 year)
-59.58%
Country
AU
Trade Neurizon Therapeutics Limited (NUZ)

Category

Healthcare
Revenue for Neurizon Therapeutics Limited (NUZ)
Revenue in Aug 2026 TTM: 0
According to Neurizon Therapeutics Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Neurizon Therapeutics Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH